Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Medicago Sativa syrup in idiopathic thrombocytopenic purpura
IRCT2017010924993N2Phase 2Completed
- Sponsor
- Vice Chancellor for Research of Mashhad University of Medical Sciences
- Start
- Feb 2017
- Countries
- 1
01
Overview
Phase 2 trial of Medicago sativa in immune thrombocytopenia (ITP), sponsored by Vice Chancellor for Research of Mashhad University of Medical Sciences. Primary endpoint: Change in platelet count. Started Feb 2017; status: completed.
02
Drugs
Medicago sativa
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on IRCT2017010924993N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2017010924993N2.